Agentis Longevity and Ultrahuman announced a strategic partnership on 31 March 2026, in Nashville, Tenn., to integrate real-time biomarker data from Ultrahuman’s platform and M1 CGM with Agentis’ proprietary Longevity Quotient (LQ).
According to the company, the integration will provide patients with a continuous, actionable health score that links wearable biosensor data to clinical intervention and personalized care. The announcement highlights a focus on user experience and wider access, and the company claims the collaboration will leverage Ultrahuman’s scalable technology and Agentis’ clinical infrastructure to deliver a premium experience at a price point aligned with inclusion.
The release cited research used to frame the initiative, noting that only 39% of U.S. adults regularly pursue preventive measures, while consumer interest indicators included 54% for genomic screening, 46% for AI-assisted diagnosis and 57% for personalized medication, and fewer than 30% reportedly discuss longevity with their doctors.
The partnership positions both firms to combine continuous metabolic monitoring with a longitudinal clinical scoring system to broaden data-driven preventive care.
